Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

Haematologica

Volumn 98, Issue 3, 2013, Pages 399-403

  Rossi, Antonella Russo ^a   Breccia, Massimo ^b   Abruzzese, Elisabetta ^c   Castagnetti, Fausto ^d   Luciano, Luigiana ^e   Gozzini, Antonella ^f   Annunziata, Mario ^g   Martino, Bruno ^h   Stagno, Fabio ⁱ   Cavazzini, Francesco ^j   Tiribelli, Mario ^k   Visani, Giuseppe ^l   Pregno, Patrizia ^m   Musto, Pellegrino ⁿ   Fava, Carmen ^o   Sgherza, Nicola ^a   Albano, Francesco ^a   Rosti, Gianantonio ^d   Alimena, Giuliana ^b   Specchia, Giorgina ^a  

^a UNIVERSITY OF BARI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g CARDARELLI HOSPITAL   (Italy)

^h BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

ⁱ Ospedale Ferrarotto   (Italy)

^j UNIVERSITY OF FERRARA   (Italy)

^k UNIVERSITY OF UDINE   (Italy)

^l SAN SALVATORE HOSPITAL   (Italy)

^m MOLINETTE HOSPITAL   (Italy)

ⁿ REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^o SAN LUIGI GONZAGA HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PLEURA EFFUSION; THROMBOCYTOPENIA; TOXICITY; TREATMENT RESPONSE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; MORTALITY; TREATMENT FAILURE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84874514362     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.064337     Document Type: Article

References (24)

1. Giles FJ, O'Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2009;23(10):1698-707.
2. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005; 11(9):3425-32.
3. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure or chronic myeloid leukemia. Blood. 2007;110(7):2242-9.
4. Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F, et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood. 2008;112(3):516-8.
5. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net. J Clin Oncol. 2009;27(35):6041-51.
6. Jabbour E, Hochhaus A, Cortes J, La Rosée P, Kantarjian HM. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia. 2010;24(1):6-12.
7. Apperley JF. Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8(12):1116-28.
8. Garg RJ, Kantarjian H, O'Brien S, Quintás-Cardama A, Faderl F, Estrov Z, et al. The use of nilotinib or dasatinib after failure to prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009;114(20):4361-8.
9. Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in bcr-abl. Curr Opin Hematol. 2004;11(1):35-43.
10. Corbin AS, Rosee PL, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 2003;101(11):4611-4.
11. Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, Giles F, et al. Dasatinib (BMS-354825) is active in Philadelphia Chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood. 2007;109(2):497-9.
12. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New Engl J Med. 2006;354(24):2531-41.
13. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. New Engl J Med. 2006;354(24):2542-51.
14. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540-6.
15. Shah NP, Kantarjian HM, Kim DW, Rea D, Dorlhiac-Llacer PE, Milone JH, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008; 26(19):3204-12.
16. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New Engl J Med. 2002;346(9):645-52.
17. Marin D, Marktel S, Bua M, Szydlo RM, Franceschino A, Nathan I, et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia. 2003;17(8):1448-53.
18. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow up of patients receiving imatinib for the first line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054-61.
19. Deininger MW, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, et al. International randomized study of interferon vs STI571(IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2009;114(22):1126.
20. Giles FJ, le Coutre P, Bhalla K, Ossenkoppele G, Alimena G, Haque A, et al. Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP), or blast crisis (BC). Blood. 2007;110(11): 1029.
21. Milojkovic D, Nicholson E, Apperley JF, Holyoake TL, Shepherd P, Drummond MW, et al. Early prediction of success or failure using second generation tyrosine kinase inhibitors for chronic myeloid leukemia. Haematologica. 2010;95(2):224-31.
22. Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S, et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood off developing additional mutations associated with resistance to secondor third-line tyrosine kinase inhibitors. Blood. 2009; 114(10):2168-71.
23. Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007;110(12):4005-11.
24. Cortes J, Kim D, Pinilla-Ibarz J, Le Coutre P, Chuah C, Nicolini F, et al. Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation. Blood. 2011;118(21):109.